You are here: Industry Insights > EIDD-2801

News List

Ridgeback and Merck report preliminary data from Covid-19 trial pharmaceutical-technology
March 09, 2021
Merck and Ridgeback Biotherapeutics have reported preliminary results from a Phase IIa trial of investigational oral antiviral agent molnupiravir EIDD-2801/MK-4482 for Covid-19.
Oral drug blocks SARS-CoV-2 transmission worldpharmanews
December 11, 2020
Treatment of SARS-CoV-2 infection with a new antiviral drug, MK-4482/EIDD-2801 or Molnupiravir, completely suppresses virus transmission within 24 hours, researchers in the Institute for Biomedical Sciences at Georgia State University have discovered.
Merck and Ridgeback Bio Collaborate contractpharma
May 28, 2020
Merck and Ridgeback Biotherapeutics LP, a closely held biotechnology company, have entered into a collaboration agreement to develop EIDD-2801.
Ridgeback Biotherapeutics announces MHRA clearance to begin human testing of EIDD-2801 in UK for COVID-19 pharmaceutical-business-review
April 16, 2020
Ridgeback Biotherapeutics announced clearance by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
FDA authorises Emory University to trial antiviral for Covid-19 pharmaceutical-technology
April 09, 2020
Emory University subsidiary DRIVE has received the US Food and Drug Administration (FDA) approval for its investigational new drug application of antiviral compound EIDD-2801 to treat Covid-19.
Ridgeback Biotherapeutics and DRIVE to develop Covid-19 drug pharmaceutical-technology
March 23, 2020
Ridgeback Biotherapeutics and Emory University’s not-for-profit Drug Innovations at Emory (DRIVE) have partnered to develop a drug candidate for potential treatment of Covid-19.